This Drug Stock Has Crushed the S&P 500 Over the Last Decade

This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Key PointsEli Lilly's GLP-1 drugs are growing fast, but competition in the new drug niche is heating up.Although the stock has performed very well over the past decade, that's no guarantee that it will continue to outperform. 10 stocks we like better than Eli Lilly › Sales of Eli Lilly's (NYSE: LLY) Mounjaro and Zepbound have been nothing short of amazing. The two GLP-1 drugs saw sales increases of 99% and 175%, respectively, in 2025. The compan…